{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:34:09Z","timestamp":1773297249707,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.lungcan.2017.03.019","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T02:16:29Z","timestamp":1490926589000},"page":"168-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies"],"prefix":"10.1016","volume":"108","author":[{"given":"J.","family":"Remon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Abedallaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Taranchon-Clermont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Bluthgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.R.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Thomas de Montpr\u00e9ville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2017.03.019_bib0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/JTO.0b013e31818e105c","article-title":"Thymoma: a focus on current therapeutic management","volume":"4","author":"Girard","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0010","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejcts.2009.05.038","article-title":"Thymoma and thymic carcinoma","volume":"37","author":"Venuta","year":"2010","journal-title":"Eur. J. Cardio-Thorac. Surg."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00428-013-1371-y","article-title":"Thymic carcinomas: clinicopathologic study of 37 cases from a single institution","volume":"462","author":"de Montpreville","year":"2013","journal-title":"VIRCHOWS Arch."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JTO.0b013e318276241c","article-title":"Thymoma: a population-based study of the management and outcomes for the province of British Columbia","volume":"8","author":"Mariano","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0030","first-page":"123","article-title":"Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy","volume":"44","author":"de Jong","year":"2008","journal-title":"Eur J. Cancer Oxf. Engl. 1990"},{"key":"10.1016\/j.lungcan.2017.03.019_bib0035","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/JTO.0000000000000017","article-title":"Staging and Prognostic Factors Committee, Members of the Advisory Boards, Participating Institutions of the Thymic Domain, The IASLC\/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies","volume":"8","author":"Detterbeck","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.lungcan.2017.03.019_bib0040","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00432-014-1800-6","article-title":"Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy","volume":"141","author":"Okuma","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0055","first-page":"7527","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"32","author":"Zucali","year":"2014","journal-title":"ASCO Meet. Abstr."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0060","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.3016","article-title":"A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors","volume":"46","author":"Petrini","year":"2014","journal-title":"Nat. Genet."},{"issue":"9, Suppl. 2","key":"10.1016\/j.lungcan.2017.03.019_bib0065","article-title":"Validation of a specific missense GT2FI mutation in more indolent thymic epithelial tumours","volume":"10","author":"Gennatas","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0070","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0075","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/JTO.0000000000000298","article-title":"State of the art of genetic alterations in thymic epithelial tumors","volume":"9","author":"Rajan","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0080","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"CLEOPATRA Study Group, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0085","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1183\/09031936.00119914","article-title":"French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas","volume":"46","author":"Lantuejoul","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0090","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lungcan.2014.05.010","article-title":"Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study","volume":"85","author":"Lattanzio","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2017.03.019_bib0100","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 World Health Organization Classification of Tumors of the Thymus: continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0105","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/annonc\/mdl077","article-title":"Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib","volume":"17","author":"Cappuzzo","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0110","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.1777","article-title":"PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor","volume":"206","author":"Torlakovic","year":"2005","journal-title":"J. Pathol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0115","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0120","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2006.06.018","article-title":"Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy","volume":"54","author":"Saijo","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2017.03.019_bib0125","first-page":"159","article-title":"Immunohistochemical detection of dipeptidyl peptidase IV (CD 26) in thyroid neoplasia using biotinylated tyramine amplification","volume":"50","author":"Kholov\u00e1","year":"2003","journal-title":"Neoplasma"},{"key":"10.1016\/j.lungcan.2017.03.019_bib0130","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e3181e392a8","article-title":"Insulin-like growth factor-1 receptor expression in thymic malignancies","volume":"5","author":"Girard","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0135","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1002\/cncr.25367","article-title":"Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas","volume":"116","author":"Zucali","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2017.03.019_bib0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrc3215","article-title":"The insulin and insulin-like growth factor receptor family in neoplasia: an update","volume":"12","author":"Pollak","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2017.03.019_bib0145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0150","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1158\/1535-7163.MCT-09-0381","article-title":"Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer","volume":"8","author":"Zha","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0155","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2008.19.9331","article-title":"Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer","volume":"27","author":"Karp","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0160","doi-asserted-by":"crossref","first-page":"e0144484","DOI":"10.1371\/journal.pone.0144484","article-title":"A potent chemotherapeutic strategy with Eg5 inhibitor against gemcitabine resistant bladder cancer","volume":"10","author":"Sun","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.lungcan.2017.03.019_bib0165","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1158\/1535-7163.MCT-15-0241","article-title":"A novel Eg5 inhibitor (LY2523355) causes mitotic arrest and apoptosis in cancer cells and shows potent antitumor activity in xenograft tumor models","volume":"14","author":"Ye","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0170","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s10637-013-0026-9","article-title":"A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma","volume":"31","author":"Hollebecque","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.lungcan.2017.03.019_bib0175","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2017.03.019_bib0180","first-page":"2528","article-title":"Overcoming the proliferation rate paradox: clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205","volume":"33","author":"Mross","year":"2015","journal-title":"ASCO Meet. Abstr."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0185","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10637-007-9097-9","article-title":"A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial","volume":"26","author":"Lee","year":"2008","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.lungcan.2017.03.019_bib0190","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","article-title":"Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma","volume":"21","author":"Leonard","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0195","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","article-title":"Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I\/II clinical trial results","volume":"10","author":"Leonard","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0200","article-title":"Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: results from an open-label extension study","author":"Wallace","year":"2015","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/19420862.2015.988944","article-title":"Antibodies to watch in 2015","volume":"7","author":"Reichert","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.lungcan.2017.03.019_bib0210","doi-asserted-by":"crossref","first-page":"561814","DOI":"10.1155\/2015\/561814","article-title":"A humanized anti-CD22-onconase antibody-drug conjugate mediates highly potent destruction of targeted tumor cells","volume":"2015","author":"Weber","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0215","doi-asserted-by":"crossref","first-page":"e0138123","DOI":"10.1371\/journal.pone.0138123","article-title":"Characterisation of a novel anti-CD52 antibody with improved efficacy and reduced immunogenicity","volume":"10","author":"Holgate","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.lungcan.2017.03.019_bib0220","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to campath-1H","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2017.03.019_bib0225","first-page":"S228","article-title":"Management of thymic tumors: a European perspective","volume":"6","author":"Ruffini","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0230","unstructured":"Future perspectives in target-specific immunotherapies of myasthenia gravis. \u2013 PubMed \u2013 NCBI, (n.d.). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26600875 (accessed 11.12.15)."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0235","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1158\/0008-5472.CAN-04-2611","article-title":"Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26\/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin","volume":"65","author":"Yamochi","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0240","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1158\/1078-0432.CCR-07-0110","article-title":"Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors","volume":"13","author":"Inamoto","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0245","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1349-7006.2009.01378.x","article-title":"The expression of dipeptidyl peptidase IV (DPPIV\/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells","volume":"101","author":"Kajiyama","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0250","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1021\/mp500483v","article-title":"Dipeptidyl peptidase IV as a potential target for selective prodrug activation and chemotherapeutic action in cancers","volume":"11","author":"Dahan","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0255","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10585-015-9736-z","article-title":"Suppression of lung metastases by the CD26\/DPP4 inhibitor Vildagliptin in mice","volume":"32","author":"Jang","year":"2015","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.lungcan.2017.03.019_bib0260","first-page":"2519","article-title":"First-in-human phase I administration of YS110, a monoclonal antibody directed against the CD26 immunostimulatory molecule in advanced cancer patients","volume":"33","author":"Angevin","year":"2015","journal-title":"ASCO Meet. Abstr."},{"key":"10.1016\/j.lungcan.2017.03.019_bib0265","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2014.58.2007","article-title":"Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial","volume":"33","author":"Lopez-Chavez","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217302830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217302830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T14:02:19Z","timestamp":1562248939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217302830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":53,"alternative-id":["S0169500217302830"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.03.019","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}